Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 5,000 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $57.03, for a total value of $285,150.00. Following the completion of the sale, the vice president now owns 33,492 shares of the company's stock, valued at $1,910,048.76. The trade was a 12.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.13, for a total value of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Trading Down 2.3 %

Akero Therapeutics stock traded down $1.28 during mid-day trading on Friday, reaching $54.08. The stock had a trading volume of 1,380,855 shares, compared to its average volume of 1,950,830. Akero Therapeutics, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $58.40. The stock's 50-day simple moving average is $30.69 and its 200-day simple moving average is $29.07. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock worth $226,554,000 after acquiring an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Akero Therapeutics during the 3rd quarter worth approximately $37,392,000. SG Americas Securities LLC raised its stake in shares of Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock worth $16,636,000 after purchasing an additional 583,486 shares during the last quarter. RTW Investments LP lifted its holdings in shares of Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company's stock valued at $169,829,000 after purchasing an additional 487,450 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Akero Therapeutics by 2.9% during the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company's stock valued at $203,053,000 after buying an additional 201,225 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on AKRO. Citigroup increased their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Morgan Stanley increased their price target on Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $35.00 to $63.00 in a research note on Thursday. UBS Group raised their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $75.86.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.